Immunotherapeutic approaches in nasopharyngeal carcinoma

References

• Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765–1777.
   PubMed Web of Science ®Google Scholar
• Cho WC. Nasopharyngeal carcinoma. In: Cancer report of Asian-Pacific region 2010. Asian Pacific Organization for Cancer Prevention. 2010:284–289.
   Google Scholar
• Au KH, Ngan RKC, Ng AWY, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018 Feb;77:16–21.
   PubMed Web of Science ®Google Scholar
• Leong YH, Soon YY, Lee KM, et al. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head Neck. 2018 Mar;40(3):622–631.
   PubMed Web of Science ®Google Scholar
• Le Q T, Dimitrios Colevas A, O’Sullivan B, et al. Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy. J Natl Cancer Inst. 2019 Jul;111(7):655–663.
   PubMedGoogle Scholar
• Lu J, Chen XM, Huang HR, et al. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma. Head Neck. 2018 Jun;40(6):1245–1253.
   PubMed Web of Science ®Google Scholar
• Huang SCM, Tsao SW, Tsang CM. Interplay of viral infection, host cell factors and tumor microenvironment in the pathogenesis of nasopharyngeal carcinoma. Cancers (Basel). 2018 Apr 4;10(4):106.
   Web of Science ®Google Scholar
• Zhang YL, Li J, Mo HY, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer. 2010 Jan;10(9):4.
   Google Scholar
• Tan GW, Visser L, Tan LP, et al. The microenvironment in Epstein-Barr Virus-associated malignancies. Pathogens. 2018 Apr 13;7(2):40.
   PubMed Web of Science ®Google Scholar
• Jones K, Nourse JP, Morrison L, et al. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood. 2010 Sep 30;116(13):2245–2252.
   PubMed Web of Science ®Google Scholar
• Li YY, Chung GT, Lui VW, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. Nat Commun. 2017 Jan;18(8):14121.
   Google Scholar
• Ogino T, Moriai S, Ishida Y, et al. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer. 2007 Jun 1;120(11):2401–2410.
   PubMed Web of Science ®Google Scholar
• Ren YX, Yang J, Zhang LJ, et al. Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients. Mol Clin Oncol. 2014 Jan;2(1):51–58.
   PubMedGoogle Scholar
• Yao M, Ohshima K, Suzumiya J, et al. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer. 1997 Jul 29;72(3):398–402.
   PubMed Web of Science ®Google Scholar
• Miao BP, Zhang RS, Li M, et al. Nasopharyngeal cancer-derived microRNA-21 promotes immune suppressive B cells. Cell Mol Immunol. 2015 Nov;12(6):750–756.
   PubMed Web of Science ®Google Scholar
• Huang PY, Guo SS, Zhang Y, et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016 Mar 15;7(11):13060–13068.
   PubMedGoogle Scholar
• Chan OS, Kowanetz M, Ng WT, et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncol. 2017;67:52–60.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014 Dec 15;5(23):12189–12202.
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994 Apr 28;330(17):1185–1191.
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 7;345(8941):9–13.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 4;115(5):925–935.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 1;108(9):2942–2949.
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012 Mar 15;119(11):2644–2656.
   PubMed Web of Science ®Google Scholar
• Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001 Oct 1;94(1):73–80.
   PubMed Web of Science ®Google Scholar
• Comoli P, De Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004 Jan;15(1):113–117.
   PubMed Web of Science ®Google Scholar
• Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005 Dec 10;23(35):8942–8949.
   PubMed Web of Science ®Google Scholar
• Huang J, Fogg M, Wirth LJ, et al. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15;123(14):2642–2650.
   PubMed Web of Science ®Google Scholar
• Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec;33(9):983–990.
   PubMed Web of Science ®Google Scholar
• Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12;113(11):2442–2450.
   PubMed Web of Science ®Google Scholar
• Lutzky VP, Crooks P, Morrison L, et al. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol. 2014 Feb;21(2):256–259.
   PubMed Web of Science ®Google Scholar
• Secondino S, Zecca M, Licitra L, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol. 2012 Feb;23(2):435–441.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood. 2005 Mar 1;105(5):1898–1904.
   PubMed Web of Science ®Google Scholar
• Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014 Jan;22(1):132–139.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883–1892.
   PubMed Web of Science ®Google Scholar
• Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012 Mar 1;72(5):1116–1125.
   PubMed Web of Science ®Google Scholar
• Smith C, Lee V, Schuessler A, et al. Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response. Oncoimmunology. 2017;6(2):e1273311.
   PubMed Web of Science ®Google Scholar
• Li J, Chen QY, He J, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015 Feb;4(2):e976507.
   PubMed Web of Science ®Google Scholar
• Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012 Feb-Mar;35(2):189–195.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan K, Liu LZ, et al. Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PLoS One. 2015;10(6):e0130620.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Zhou S, Chen CL, et al. Clinical effect of adjuvant cytokine-induced killer cells immunotherapy in patients with Stage II-IVB nasopharyngeal carcinoma after chemoradiotherapy: a propensity score analysis. J Cancer. 2018;9(22):4204–4214.
   PubMed Web of Science ®Google Scholar
• Lin CL, Lo WF, Lee TH, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002 Dec 1;62(23):6952–6958.
   PubMed Web of Science ®Google Scholar
• Chia WK, Wang WW, Teo M, et al. A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2012 Apr;23(4):997–1005.
   PubMed Web of Science ®Google Scholar
• Taylor GS, Jia H, Harrington K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014 Oct 1;20(19):5009–5022.
   PubMed Web of Science ®Google Scholar
• Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013 Mar 15;73(6):1676–1688.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 Jan 12;393(10167):156–167.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374–1385.
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542–2552.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm Phase II checkMate 205 trial. J Clin Oncol. 2018 May 10;36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125–2132.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940–952.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fang W, Qin T, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015 Mar;32(3):86.
   PubMed Web of Science ®Google Scholar
• Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014 Aug;46(8):866–871.
   PubMed Web of Science ®Google Scholar
• Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017 Dec 20;35(36):4050–4056.
   PubMed Web of Science ®Google Scholar
• Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018 May 10;36(14):1412–1418.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338–1350.
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003 Jun;39(4):361–366.
   PubMed Web of Science ®Google Scholar
• Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002 Jan;13(1):150–156.
   PubMed Web of Science ®Google Scholar
• Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol. 2011 Mar;22(3):718–722.
   PubMed Web of Science ®Google Scholar
• Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr Virus DNA in Nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018 Jul 10;36(31):3091–3100.
   Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509–1520.
   PubMed Web of Science ®Google Scholar
• Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019 May 31.
   Web of Science ®Google Scholar
• Magalhaes I, Carvalho-Queiroz C, Hartana CA, et al. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opin Biol Ther. 2019 Apr 15.
   PubMedGoogle Scholar
• Wu YL, Ding YP, Tanaka Y, et al. gammadelta T cells and their potential for immunotherapy. Int J Biol Sci. 2014;10(2):119–135.
   PubMed Web of Science ®Google Scholar
• Zou C, Zhao P, Xiao Z, et al. gammadelta T cells in cancer immunotherapy. Oncotarget. 2017 Jan 31;8(5):8900–8909.
   PubMedGoogle Scholar
• Fisher J, Anderson J. Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front Immunol. 2018;9:1409.
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Lizotte P, Cavanaugh M, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 Feb 22;3:4.
   Web of Science ®Google Scholar
• Oliva M, Spreafico A, Taberna M, et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2019 Jan 1;30(1):57–67.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Illidge TM. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology. 2015 Jul;4(7):e1016709.
   PubMed Web of Science ®Google Scholar
• Danny Rischin KH, Greil R, Soulieres D, editor. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 2019.
   Google Scholar